Seroatlas · Human Serome Atlas

PRKAR2B

cAMP-dependent protein kinase type II-beta regulatory subunit

Also known as: KAP3_HUMAN, PRKAR2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P31323
Gene
PRKAR2B
Ensembl
ENSG00000005249
Chromosome
7
Canonical length
418 aa
Protein class
Predicted intracellular proteins
Subcellular location
Golgi apparatus,Centrosome,Basal body,Cytosol

OverviewNCBI Gene

cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. The protein encoded by this gene is one of the regulatory subunits. This subunit can be phosphorylated by the activated catalytic subunit. This subunit has been shown to interact with and suppress the transcriptional activity of the cAMP responsive element binding protein 1 (CREB1) in activated T cells. Knockout studies in mice suggest that this subunit may play an important role in regulating energy balance and adiposity. The studies also suggest that this subunit may mediate the gene induction and cataleptic behavior induced by haloperidol. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

418 residues, UniProt reviewed canonical sequence.

>P31323|PRKAR2B
     1  MSIEIPAGLT ELLQGFTVEV LRHQPADLLE FALQHFTRLQ QENERKGTAR FGHEGRTWGD
    61  LGAAAGGGTP SKGVNFAEEP MQSDSEDGEE EEAAPADAGA FNAPVINRFT RRASVCAEAY
   121  NPDEEEDDAE SRIIHPKTDD QRNRLQEACK DILLFKNLDP EQMSQVLDAM FEKLVKDGEH
   181  VIDQGDDGDN FYVIDRGTFD IYVKCDGVGR CVGNYDNRGS FGELALMYNT PRAATITATS
   241  PGALWGLDRV TFRRIIVKNN AKKRKMYESF IESLPFLKSL EFSERLKVVD VIGTKVYNDG
   301  EQIIAQGDSA DSFFIVESGE VKITMKRKGK SEVEENGAVE IARCSRGQYF GELALVTNKP
   361  RAASAHAIGT VKCLAMDVQA FERLLGPCME IMKRNIATYE EQLVALFGTN MDIVEPTA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRKAR2B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.39
Highest tissue expression
160 nTPM

Expression across tissuesHPA

Tissue

  • adipose tissue: 160 nTPM
  • breast: 50 nTPM
  • adrenal gland: 43 nTPM
  • cerebral cortex: 31 nTPM
  • basal ganglia: 31 nTPM
  • ovary: 25 nTPM

Single-cell type

  • platelets: 1,661 nCPM
  • megakaryocytes: 1,076 nCPM
  • adipocytes: 708 nCPM
  • megakaryocyte progenitors: 380 nCPM
  • megakaryocyte-erythroid progenitors: 372 nCPM
  • granulosa cells: 329 nCPM

Immune cell

  • myeloid DC: 0.5 nTPM
  • total PBMC: 0.5 nTPM
  • intermediate monocyte: 0.3 nTPM
  • NK-cell: 0.2 nTPM
  • plasmacytoid DC: 0.1 nTPM
  • basophil: 0 nTPM

Brain region

  • cerebral cortex: 11 nTPM
  • basal ganglia: 10 nTPM
  • midbrain: 9.9 nTPM
  • hippocampal formation: 7.4 nTPM
  • white matter: 7.2 nTPM
  • pons: 6.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.22
gnomAD pLI
1
gnomAD missense Z
2.47
DepMap mean gene effect
0.07
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PRKAR2B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRKAR2B as an antibody target. Whether an autoantibody or antibody against PRKAR2B could matter depends on whether native PRKAR2B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRKAR2B is annotated at the cell surface, where native PRKAR2B is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PRKAR2B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PRKAR2B. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...